The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART

Completed · Phase 2

Conditions studied: HIV Seropositivity, HIV Infection

In brief

This is an open-label, prospective, randomized, controlled study of the safety and efficacy including clinical, immunologic, and virologic assessments of adding Ampligen to a Strategic Therapeutic Intervention (STI) of HAART in patients with plasma HIV RNA \< 50 copies/ml (PCR) and CD4 levels \> 400.

Key facts

Study ID

NCT00035893

Run by

AIM ImmunoTech Inc.

People needed

40

Starts

2001-05-01

Expected to finish

2006-08-01

Last updated by the study team

2013-04-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Orange County Center for Special Immunology — Fountain Valley, California, United States
• AltaMed Health Services Corporation — Los Angeles, California, United States
• Circle Medical Center — Norwalk, Connecticut, United States
• Dupont Circle Physicians Group — Washington D.C., District of Columbia, United States
• Julia Torres, MD — Fort Lauderdale, Florida, United States
• Allied Clinical Trials — Miami, Florida, United States
• Scott Ubillos, MD — Tampa, Florida, United States
• St. Michael's Medical Center — Newark, New Jersey, United States
• Christopher Lucasti, D.O. — Somers Point, New Jersey, United States
• W. Chris Woodward, DO — Reading, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.